MYGN - ミリアド・ジェネティックス (Myriad Genetics Inc.)

MYGNのニュース

   Midday Gainers / Losers  2019-05-08
Gainers: Attis Industries (NASDAQ: ATIS ) +49% . MACOM Technology Solutions Holdings (NASDAQ: MTSI ) +28% . Akorn (NASDAQ: AKRX ) +28% . Chanticleer Holdings (NASDAQ: BURG ) +26% . Corindus Vascular Robotics (NYSEMKT: CVRS ) +21% . Avalara (NYSE: AVLR ) +20% . Conformis (NASDAQ…
   Myriad Genetics down 22% on FQ3 revenue miss, softer guidance  2019-05-08
Myriad Genetics ( MYGN -21.8% ) slumps on triple normal volume following its fiscal Q3 report released after the close yesterday. Highlights: More news on: Myriad Genetics, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more …
   Myriad Genetics, Inc. (MYGN) CEO Mark Capone on Q3 2019 Results - Earnings Call Transcript  2019-05-07
Call Start: 16:30 Call End: 17:21 Myriad Genetics, Inc. (MYGN) Q3 2019 Earnings Conference Call May 7, 2019 16:30 ET Corporate Participants Scott Gleason - Vice President of Investor Relations Mark Capone - President and Chief Executive Officer Bryan Riggsbee - Chief Financia…
   Myriad Genetics, Inc. 2019 Q3 - Results - Earnings Call Slides  2019-05-07
The following slide deck was published by Myriad Genetics, Inc. in conjunction with their 2019 Q3 earnings Read more …
   Myriad expands partnership with AstraZeneca and Merck  2019-04-04
Myriad Genetics(NASDAQ: MYGN ) has expanded its companion diagnostic collaboration with AstraZeneca (NYSE: AZN ) and Merck (NYSE: MRK ). More news on: Myriad Genetics, Inc., AstraZeneca PLC, Merck & Co., Inc., Healthcare stocks news, Read more …
   FDA OKs expanded use for AstraZeneca's Lynparza  2018-12-19
AstraZeneca ( AZN -0.8% ) and collaboration partner Merck ( MRK -0.8% ) announce that the FDA has approved PARP inhibitor LYNPARZA (olaparib) as maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advance…

calendar